| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
5-HT2 Receptor D2 Receptor
Dopamine D2 receptor (antagonist); 5-HT2A receptor (antagonist). Blonanserin-d5 has no independent pharmacology as an internal standard. |
|---|---|
| ln Vitro |
As the parent compound, Blonanserin is a dopamine D2/5-HT2 receptor antagonist and an atypical antipsychotic. It exhibits high selectivity for dopamine D2 and serotonin 5-HT2 receptors, with a favorable extrapyramidal symptom (EPS) profile compared to classical antipsychotics. As a stable isotope-labeled internal standard, Blonanserin-d5 has no independent activity.
|
| ln Vivo |
Cellular activity data for the deuterated form are not specifically reported. The non-deuterated Blonanserin is an atypical antipsychotic primarily used in the treatment of schizophrenia. It acts as a dopamine D2 and 5-HT2 receptor antagonist, modulating dopaminergic and serotonergic signaling pathways in the central nervous system, which contributes to its antipsychotic efficacy with a lower risk of extrapyramidal side effects.
|
| Enzyme Assay |
Radioligand binding assays for dopamine D2 and 5-HT2A receptors are performed using membrane preparations from CHO cells expressing human receptors. [3H]-spiperone is used as the radioligand for D2 binding. [3H]-ketanserin is used for 5-HT2A binding. Non-deuterated Blonanserin is the reference standard. Blonanserin-d5 is not used in these functional assays.
|
| Cell Assay |
For analytical method development, typical protocols involve LC-MS/MS analysis. Biological samples (plasma, serum, or tissue homogenates) are spiked with Blonanserin-d5 as an internal standard at a fixed concentration (e.g., 1-50 ng/mL). Samples are processed by protein precipitation with acetonitrile or methanol, or by solid-phase extraction (SPE). The supernatant is injected onto a reverse-phase C18 column with a mobile phase of water/acetonitrile containing 0.1% formic acid. Detection is by MRM in positive ion mode, using specific transitions for Blonanserin and Blonanserin-d5 (mass shift due to 5 deuterium atoms). Peak area ratios are used for quantification over a validated concentration range.
|
| Animal Protocol |
Pharmacokinetic (PK) studies in animals and humans utilize Blonanserin-d5 as the bioanalytical internal standard. For in vivo studies in rats or dogs, Blonanserin is administered intravenously or orally. Serial blood samples are collected over 24-72 hours. Plasma samples are processed with Blonanserin-d5 as described above. PK parameters such as Cmax, tmax, t1/2, AUC, CL, and Vd are calculated from the concentration-time curve using non-compartmental analysis.
|
| ADME/Pharmacokinetics |
Blonanserin-d5 is the deuterated internal standard version of Blonanserin. As a stable isotope-labeled analog, it mimics the physicochemical properties of the non-labeled drug but has no independent pharmacokinetic profile. In LC-MS/MS quantification, it elutes at the same retention time as Blonanserin, allowing for accurate quantification of the parent drug without isotopic interference. Incorporation of deuterium enhances metabolic stability for analytical purposes.
|
| Toxicity/Toxicokinetics |
Toxicity data for Blonanserin-d5 are not applicable as it is an analytical standard. The non-deuterated Blonanserin is an approved atypical antipsychotic in several countries (Japan, China, South Korea) for schizophrenia. Common side effects include akathisia, extrapyramidal symptoms, somnolence, and increased prolactin. Serious adverse effects include neuroleptic malignant syndrome and tardive dyskinesia.
|
| References | |
| Additional Infomation |
Blonanserin-d5 is a stable isotope-labeled internal standard used exclusively for pharmaceutical research and analytical applications. The parent drug Blonanserin was first approved in Japan in 2008 for the treatment of schizophrenia. The deuterated version facilitates accurate quantitation in pharmacokinetic studies, therapeutic drug monitoring, and bioequivalence studies, and is used for analytical method development and validation during drug manufacturing. This compound is not a therapeutic agent and has no approved clinical indications.
|
| Molecular Formula |
C23H25D5FN3
|
|---|---|
| Molecular Weight |
372.53
|
| Exact Mass |
372.273
|
| CAS # |
1346599-86-7
|
| Related CAS # |
Blonanserin;132810-10-7;Blonanserin dihydrochloride;132812-45-4;Blonanserin-d8
|
| PubChem CID |
71314128
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.1±0.1 g/cm3
|
| Boiling Point |
540.8±50.0 °C at 760 mmHg
|
| Flash Point |
280.9±30.1 °C
|
| Vapour Pressure |
0.0±1.4 mmHg at 25°C
|
| Index of Refraction |
1.557
|
| LogP |
6.03
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
27
|
| Complexity |
443
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1CCC2N=C(N3CCN(C([2H])([2H])C([2H])([2H])[2H])CC3)C=C(C3C=CC(F)=CC=3)C=2CCC1
|
| InChi Key |
XVGOZDAJGBALKS-ZBJDZAJPSA-N
|
| InChi Code |
InChI=1S/C23H30FN3/c1-2-26-13-15-27(16-14-26)23-17-21(18-9-11-19(24)12-10-18)20-7-5-3-4-6-8-22(20)25-23/h9-12,17H,2-8,13-16H2,1H3/i1D3,2D2
|
| Chemical Name |
4-(4-fluorophenyl)-2-[4-(1,1,2,2,2-pentadeuterioethyl)piperazin-1-yl]-5,6,7,8,9,10-hexahydrocycloocta[b]pyridine
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.6843 mL | 13.4217 mL | 26.8435 mL | |
| 5 mM | 0.5369 mL | 2.6843 mL | 5.3687 mL | |
| 10 mM | 0.2684 mL | 1.3422 mL | 2.6843 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
